Skip to main content
. 2017 Mar 29;8(19):31959–31976. doi: 10.18632/oncotarget.16657

Figure 7. Aberrant TIMP3 DNA methylation levels in AML patients are associated with an adverse cytogenetic prognosis.

Figure 7

(A) The TIMP3 DNA methylation levels were quantified by pyrosequencing in bone marrow cells obtained at diagnosis from 90 AML patients and from 25 healthy donors. Each sample is represented by a black dot. (B) Pie charts indicating the frequency of AML patients with aberrant DNA methylation levels (> 20%) for TIMP3 by cytogenetic prognosis group (favorable, intermediate and adverse) of AML patients.